[Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?].

Objective: To evaluate the relationship between the level of glial fibrillary acidic protein (GFAP) in the blood and the rate of progression (RP) of neurological disorders and exacerbation frequency of multiple sclerosis (MS) in the presence/absence of traumatic brain injury (TBI) before the onset of MS.

Material And Methods: Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (mean age 36.1±9.

[Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].

Objective: To evaluate the severity and frequency of infusion reactions (IR) in patients with highly active relapsing-remitting multiple sclerosis (MS) In Russian population receiving alemtuzumab therapy.

Material And Methods: In retrospective study, we analyzed data from 50 patients with highly active relapsing-remitting multiple sclerosis (MS) from six Regional MS Centers in the Russian Federation who received two courses of alemtuzumab between 2018 and 2022.

Results: Among all IRs, the most frequently reported were hives-like rashes, which were registered in 27 people, mostly of mild severity (70.

[Traumatic brain injury before the multiple sclerosis onset: a relationship with the progression of neurological disorders and pathobiochemical markers of the cerebrospinal fluid].

Objective: To evaluate the association of traumatic brain injury (TBI) before the multiple sclerosis (MS) onset with the rate of progression of neurological disorders and cerebrospinal fluid markers of blood-brain barrier permeability, inflammation, demyelination, and gliosis.

Material And Methods: Patients with relapsing-remitting MS in the Altai region of Russia with/without TBI before the MS onset (44; 19 men, 25 women in each group) participated in a prospective, controlled, randomized study. Disability rate was assessed retrospectively.

[Association of vitamin D metabolism enzyme gene polymorphisms with multiple sclerosis risk: pilot study].

Objective: To evaluate the association polymorphisms in genes coding for enzymes involved in vitamin D metabolism (rs703842) and (rs2248359) with the risk of multiple sclerosis (MS).

Material And Methods: Ninety Caucasian patients with remitting MS and 87 volunteers without MS, born and living in the Altai region of Russia, participated in the study. Genotyping was performed by the TaqMan probe method.

[Multiple sclerosis in the Altai region of Russia: a prospective epidemiological study].

Aim: Analysis of the dynamics of epidemiological indicators of multiple sclerosis (MS) in the Altai region of the Russian Federation for the period from 2009 to 2017.

Material And Methods: A comparative analysis of the prevalence, incidence and main clinical characteristics of MS in the Altai region was carried out based on the data of patients with MS from 2009 (1001 patients) to 2017 (1322 patients).

Results And Conclusion: The prevalence of MS increased from 41.